View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
October 7, 2012

Janssen Scientific Affairs launches JanssenMD web-based application

Janssen Scientific Affairs has introduced JanssenMD, a new medical information tool for accessing drug information and clinical resources through desktops, tablets, and smartphones in the US.

Janssen Scientific Affairs has introduced JanssenMD, a new medical information tool for accessing drug information and clinical resources through desktops, tablets, and smartphones in the US.

The new web-based application and online scientific resource is designed to enable access to current information about Janssen products marketed in the US.

Janssen Scientific Affairs chief scientific officer Dr. Norm Rosenthal said JanssenMD was created to provide healthcare professionals with the information they need, when, where, and how they need it.

"This unique digital platform enables us to respond to healthcare professionals’ questions with information that is current, accurate, and instantly accessible from any device they are using," Dr. Rosenthal added.

JanssenMD’s search functionality enables clinicians to identify full prescribing information, clinical trial data, and safety information about Janssen medications.

The company claims that it is the among the first medical information websites to offer a self-service model that is accessible through mobile devices.

Besides product information, the web-based application provides access to Janssen prescription assistance programmes and risk evaluation and mitigation tools.

At present, JanssenMD provides scientific information for five pharmaceutical products Edurant (rilpivirine), Remicade (infliximab), Stelara (ustekinumab), Xarelto (rivaroxaban), and Zytiga (abiraterone acetate); additional Janssen products will be added over time.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena